156496-89-8

Basic information

• Product Name: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate;1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-3-oxo-, 1,1-diMethylethyl ester;tert-butyl 3-oxo-1,2,3,6-tetrahydropyridine-1-carboxylate;tert-Butyl 3-oxo-3,6-dihydropyridine-1(2H)-carboxylate;tert-Butyl 3-oxo-2,6-dihydropyridine-1-carboxylate
• CAS NO: 156496-89-8
• Molecular Formula: C₁₀H₁₅NO₃
• Molecular Weight: 197.231
• Mol File: 156496-89-8.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 299.2±39.0 °C(Predicted)
• Appearance: /
• Density: 1.130±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.95±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(156496-89-8)
• EPA Substance Registry System: tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate(156496-89-8)

Safety Data

• Hazardous Substances Data: 156496-89-8(Hazardous Substances Data)

Usage

Description

tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate is an organic compound with the molecular formula C10H15NO3. It is a derivative of pyridine, a heterocyclic compound with a six-membered ring containing one nitrogen atom. This specific compound features a five-membered dihydropyridine ring fused to the pyridine ring, with a ketone group at the 5-position and a carboxylate group at the 1-position. The tert-butyl group is attached to the 5-oxo position, providing steric hindrance and stability to the molecule.

Uses

Used in Chemical Synthesis:
tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate is used as a reagent for the preparation of ω-alkoxy enones and α-amino enones from unsaturated alcohols or unsaturated amines. The compound serves as a key intermediate in the synthesis of these enones, which are valuable building blocks in organic chemistry and have various applications in the pharmaceutical and chemical industries.
The process involves the formation of intermediate phosphoranes, which are then subjected to ring-closing metathesis to yield the desired enones. This method provides a convenient and efficient route to synthesize a range of enone derivatives with potential applications in the development of new drugs, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate may be used as a starting material or intermediate for the synthesis of various drug candidates. The compound's unique structure and reactivity make it a promising candidate for the development of new therapeutic agents, particularly those targeting cardiovascular diseases, as dihydropyridines are known for their calcium channel-blocking properties.
Additionally, the compound's versatility in chemical synthesis allows for the exploration of its potential in the development of other therapeutic areas, such as anti-inflammatory, anti-cancer, and anti-infective agents.
Used in Material Science:
In the field of material science, tert-Butyl 5-oxo-5,6-dihydropyridine-1(2H)-carboxylate may find applications in the development of novel materials with specific properties. For instance, the compound could be used as a building block in the synthesis of new polymers, dyes, or sensors, taking advantage of its unique chemical structure and reactivity.

Upstream product

• 224779-27-5 tert-butyl 3-hydroxy-1,2,3,6-tetrahydropyridine-N-carboxylate 
• 120568-74-3 N-allyl-N-(2-hydroxy-3-butenyl)amine 
• 224779-26-4 N-allyl-N-(2-hydroxy-but-3-enyl)-carbamic acid tert-butyl ester 
• 691-64-5 di-tert-butyl oxalate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 141699-59-4 1-(tert-butoxycarbonyl)piperidin-4-yl methanesulfonate 
• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 
• 161157-50-2 tert-butyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 942056-42-0 tert-butyl allyl[2-oxo-3-(triphenyl-λ⁵-phosphoranylidene)prop-1-yl]carbamate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 156496-90-1 3-(2,6-Dichloro-phenyl)-4-oxo-4,5,7,7a-tetrahydro-3aH-isoxazolo[5,4-c]pyridine-6-carboxylic acid tert-butyl ester 
• 1268716-52-4 1-(4-bromo-benzyl)-5-(2-methyl-1H-indol-3-yl)-piperidin-3-one 
• 1373492-32-0 (2-chlorophenyl)-(3-oxo-3,6-dihydro-2H-pyridin-1-yl)acetic acid methyl ester 
• 1373492-33-1 (2-chlorophenyl)-(3-mercapto-5-oxopiperidin-1-yl)acetic acid methyl ester 
• 1373492-34-2 3-tert-butoxycarbonylmethylene-5-(mercaptopiperidin-1-yl)-(2-chlorophenyl)acetic acid methyl ester 
• 1373491-56-5 (3-carboxymethylene-5-mercaptopiperidin-1-yl)-(2-chlorophenyl)acetic acid methyl ester hydrochloride 

Relevant articles and documents

Discovery of a Cyclic Choline Analog That Inhibits Anaerobic Choline Metabolism by Human Gut Bacteria

The anaerobic conversion of choline to trimethylamine (TMA) by the human gut microbiota has been linked to multiple human diseases. The potential impact of this microbial metabolic activity on host health has inspired multiple efforts to identify small molecule inhibitors. Here, we use information about the structure and mechanism of the bacterial enzyme choline TMA-lyase (CutC) to develop a cyclic choline analog that inhibits the conversion of choline to TMA in bacterial whole cells and in a complex gut microbial community. In vitro biochemical assays and a crystal structure suggest that this analog is a competitive, mechanism-based inhibitor. This work demonstrates the utility of structure-based design to access inhibitors of radical enzymes from the human gut microbiota.

DIPEPTIDE PIPERIDINE DERIVATIVES

The disclosure relates to pharmaceutical compositions, to methods of preparing such compositions, and to methods for using such compositions for treating or preventing a disease or condition associated with arginase activity.

PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS

Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa)